Previous close | 67.08 |
Open | 67.45 |
Bid | 65.26 x 400 |
Ask | 65.33 x 200 |
Day's range | 65.09 - 67.90 |
52-week range | 65.09 - 87.87 |
Volume | |
Avg. volume | 7,349,480 |
Market cap | 83.647B |
Beta (5Y monthly) | 0.20 |
PE ratio (TTM) | 14.90 |
EPS (TTM) | N/A |
Earnings date | N/A |
Forward dividend & yield | 3.08 (4.59%) |
Ex-dividend date | 14 Mar 2024 |
1y target est | N/A |
Although the revenue and EPS for Gilead (GILD) give a sense of how its business performed in the quarter ended March 2024, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.
The biotech reported a loss for the quarter of $1.32 per share, better than the FactSet consensus estimate of a loss of $1.49 per share.
Comprehensive Analysis of Gilead's First Quarter Financial Performance